Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication 50% Dextrose Injection is indicated in the treatment of insulin hypoglycemia (hyperinsulinemia or insulin shock) to restore blood glucose levels. The solution is also indicated, after dilution, for intravenous infusion as a source of carbohydrate calories in patients whose oral intake is restricted or inadequate to maintain nutritional requirements.
Dextrose · 1 trial · 2 indications
Endothelium-dependent brachial artery flow-mediated dilation (FMD) was assessed. Ultrasound images of the brachial artery were obtained and arterial diameters were measured with customized software. Brachial artery FMD was calculated as (hyperemic diameter - baseline diameter)/baseline diameter × 100.
| Arm | Type | Description |
|---|---|---|
| Healthy Volunteer | ACTIVE_COMPARATOR | Subjects receive 24 hours of infusion of 0.9% normal saline, dextrose (sugar) without fat, ClinOleic (olive oil-based), and Intralipid (soybean-derived fat) |
| Name | Type | Description |
|---|---|---|
| Intralipid | DRUG | Infusion of Intralipid (soybean-derived fat) |
| ClinOleic | DRUG | Infusion of ClinOleic (olive oil-based) |
| Dextrose | DRUG | Infusion of dextrose (sugar) without fat |
| Saline (control) | OTHER | Infusion of 0.9% normal saline |
Inclusion Criteria: * Healthy males or females, BMI 25 - 35 kg/m2, between the ages of 18 and 65 years Exclusion Criteria: * The patient is pregnant or breast feeding * Subjects have or with history of diabetes, hypertension, fasting triglyceride levels \> 250 mg/dL, liver disease (ALT 2.5x \> up...
Dextrose is a small molecule developed by Baxter International Inc. for metabolic diseases. It has been studied in a Phase 2 trial involving healthy volunteers to evaluate metabolic and insulin sensitivity effects. Dextrose is commonly used as a source of carbohydrate in clinical settings, but its specific investigational use here focuses on metabolic conditions.
Dextrose is developed by Baxter International Inc., which trades under the ticker symbol BAX. Baxter is a global medical products company that manufactures a range of healthcare products, including intravenous solutions and nutritional therapies.
Dextrose is in Phase 2 clinical development. One Phase 2 trial has been completed, and there are currently no active trials. The trial enrolled 12 participants and was active-controlled, comparing lipid emulsions in healthy volunteers.
Dextrose has been studied in a completed Phase 2 trial, NCT02185729, titled "Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers." The trial enrolled 12 healthy volunteers in the United States and examined metabolic and insulin sensitivity outcomes.
Dextrose is an investigational product in Phase 2 development for metabolic diseases. It has not been approved by the FDA for the studied indication. The completed Phase 2 trial evaluated its effects in healthy volunteers, but further clinical development would be required for potential approval.